Myasthenia Gravis Therapeutic Pipeline Drugs and Companies Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Mon Dec 15, 2:31PM CST
The report "Myasthenia Gravis Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Myasthenia gravis is an either auto-immune or genetic neuromuscular illness that results in varying muscular weak point and fatigue. Complete Report is Available @ http://www.rnrmarketresearch.com/myasthenia-g...eport.html .
CYTK: 4.57 (+0.09), PFE: 30.67 (-0.19), GSK: 41.92 (+0.62)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.23 (+0.02), PCYC: 129.56 (+1.12), TGTX: 16.78 (-0.22), ONTX: 3.94 (-0.12), BMY: 57.69 (-0.86), GSK: 41.92 (+0.62), AZN: 69.56 (-0.18), ABBV: 65.25 (-0.37), INFI: 16.13 (+0.55), CELGZ: 3.29 (-0.18), NVS: 91.65 (+0.01)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 8.70 (-0.16), NPSP: 30.47 (+0.39), AMGN: 159.44 (-0.16), NKTR: 14.47 (-0.03)
High Triglyceridemia - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pnv28/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acasti Pharma - Actavis - Alnylam - Arisaph - Astellas Pharma - AstraZeneca - Cardax Pharmaceuticals - Catabasis Pharmaceuticals - Essentialis - Isis Pharmaceuticals - Novartis - Pharmena - Poxel - Tekmira Pharmaceuticals - Thetis Pharmaceuticals - Trygg Pharma For more information visit http://www.researchandmarkets.com/research/4pnv28/high
ACST: 0.54 (-0.02), ISIS: 54.94 (-1.99), TKMR: 13.12 (-0.19), NVS: 91.65 (+0.01)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 71.62 (-0.52), AZN: 69.56 (-0.18), AMGN: 159.44 (-0.16), ONTX: 3.94 (-0.12), GSK: 41.92 (+0.62), STML: 15.28 (-0.21)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.35 (-0.17), LXRX: 0.86 (+0.01), LLY: 69.26 (-0.41), GSK: 41.92 (+0.62), MNTA: 11.00 (-0.43)
Urinary Incontinence - Pipeline Review, H2 2014
M2 - Thu Dec 04, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/c4f87w/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Allergan - Astellas Pharma - Beech Tree Labs - Cook MyoSite - Evotec - FemmePharma Global Healthcare - Innovacell Biotechnologie - Recordati - TheraVida For more information visit http://www.researchandmarkets.com/research/c4f87w/urinary
AGN: 205.75 (-3.26)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 110.86 (-2.02), AMGN: 159.44 (-0.16), LLY: 69.26 (-0.41), BMY: 57.69 (-0.86), NKTR: 14.47 (-0.03), AGN: 205.75 (-3.26), IPXL: 29.09 (-1.55), ALDR: 24.79 (-0.77), QCOR: 93.60 (+1.52), MRK: 56.80 (-0.15), TSPT: 1.70 (-0.04), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10)
Aspergillosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/7g634d/aspergillosis) has announced the addition of the "Aspergillosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Aspergillosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amplyx Pharmaceuticals, Inc. - Astellas Pharma Inc. - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Eisai Co., Ltd. - F2G Ltd - iCo Therapeutics Inc. - MABLife S.A.S - Merck & Co., Inc. - Novabiotics Ltd - Pulmocide Ltd - Sealife PHARMA GMBH - Sigma-Tau S.p.A. For more information visit http://www.researchandmarkets.com/research/7g...ergillosis
MRK: 56.80 (-0.15)
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014
M2 - Mon Dec 01, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/22wv9l/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - Adamis - Aeterna Zentaris - Alethia Biotherapeutics - Amgen - AnGes MG - Antoxis - Aphios - Armour - Arno - Astellas Pharma - Astex - AstraZeneca - Ausio - Bavarian Nordic - Bayer - Beta Pharma - Bio-Cancer Treatment International - Biscayne - Boehringer Ingelheim - Celldex - CureTech - CytoVac A/S - DexTech Medical - Enceladus BV - Endo - EndoCeutics - Endocyte - Errant Gene - Fujifilm - Genentech - Glactone Pharma - GlaxoSmithKline - GTx - Harbor - Hybrigenics - Incuron - Io - Isis - Johnson & Johnson - Kinex - Medivation - Medvio Eurasia - Merck KGaA - Millennium - NewLink Genetics - Novartis AG - Oncogenex - Orion Oyj - Orphagen - Oxford BioMedica - Panacela Labs - Tokai - Viamet For more information visit http://www.researchandmarkets.com/research/22wv9l/hormone
JNJ: 102.76 (-1.20), NLNK: 33.10 (-0.36), AMGN: 159.44 (-0.16), GSK: 41.92 (+0.62), NVS: 91.65 (+0.01)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 28.79 (-0.20), AMGN: 159.44 (-0.16), BMY: 57.69 (-0.86), CTIC: 2.21 (-0.01), GSK: 41.92 (+0.62), VSTM: 8.20 (+0.01), SNTA: 2.66 (+0.02), SGEN: 31.86 (+0.45), MRK: 56.80 (-0.15), AMBI: 15.60 (+0.26), CELGZ: 3.29 (-0.18), KPTI: 31.07 (-0.82), NVS: 91.65 (+0.01)
Research and Markets: Global Irritable Bowel Syndrome Market 2015-2019: Key Vendors are Actavis, Astellas Pharma, Nestle and Takeda Pharmaceutical
Business Wire - Tue Nov 25, 6:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/wq3rtp/global_irritable) has announced the addition of the "Global Irritable Bowel Syndrome Market 2015-2019" report to their offering.
Global Irritable Bowel Syndrome Market 2015-2019: Key Vendors are Actavis, Astellas Pharma, Nestle and Takeda Pharmaceutical
M2 - Tue Nov 25, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6f6s/global_irritable) has announced the addition of the "Global Irritable Bowel Syndrome Market 2015-2019" report to their offering. One major trend upcoming in this market is an increase in public awareness about irritable bowel syndrome, which is expected to increase the number of treatment-seeking patients, thereby increasing the consumption of medications. Growing public awareness increases the number of treatment-seeking patients, thereby leading to increased consumption of approved medications. According to the report, the presence of huge unmet needs in the field of irritable bowel syndrome is one of the major drivers of the market. There is a lack of a significant number of drugs approved by the FDA, and the use of generics and off-label drugs causes erosion in the market share of labeled products. This provides vendors with an opportunity to produce new drugs, which can give them an edge over others and hence, grab a major portion of the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Market Segmentation by Mechanism of Action 09. Market Segmentation by Dosage Form 10. Market Segmentation by Indication 11. Market Segmentation by End User Gender 12. Geographical Segmentation 13. Rate of Incidence and Prevalence 14. Buying Criteria 15. Market Growth Drivers 16. Drivers and their Impact 17. Market Challenges 18. Impact of Drivers and Challenges 19. Market Trends 20. Trends and their Impact 21. Vendor Landscape 22. Pipeline Portfolio 23. Key Vendor Analysis 24. Other Reports in this Series Companies Mentioned: - Abbott - Actavis - Alba Therapeutics - Alfa Wassermann - Alizyme - Almirall - AltheRx - Ardelyx - Astellas Pharma - AstraZeneca - Bayer - Bristol Myers Squibb - Dainippon Sumitomo Pharma - Dong-A Socio Holdings - DraisPharmaceuticals - Dynogen - GlaxoSmithKline - Hanmi - ImmusanT - Ironwood - Janssen - Lexicon - Menarini - MicroDose Therapeutx - Nestle - Norgine - Novartis - Ocera Therapeutics - Ono Pharmaceutical - ParPharmaceutical For more information visit http://www.researchandmarkets.com/research/8z..._irritable
OCRX: 5.71 (-0.25), GSK: 41.92 (+0.62), NVS: 91.65 (+0.01)
Schizophrenia Therapeutics Market 2018 - First-Generation and Second-Generation Antipsychotics Segments Analyzed at ReportsnReports.com
PRWeb - Mon Nov 24, 11:30PM CST
Schizophrenia is a condition in which people interpret reality abnormally. The symptoms of schizophrenia can be managed through medication and psychological therapy. Increase in aging population, increased incidences of schizophrenia and rising awareness about mental illnesses are some of the key factors which are propelling the growth of the global schizophrenia therapeutics market. Awareness about schizophrenia among physicians and patients is also going to be a major factor which will increase the demand of schizophrenia drugs in the market.
JNJ: 102.76 (-1.20), ABT: 43.40 (-0.06), ACAD: 30.02 (-0.32), PFE: 30.67 (-0.19), MRK: 56.80 (-0.15), AZN: 69.56 (-0.18), GSK: 41.92 (+0.62), BMY: 57.69 (-0.86), NVS: 91.65 (+0.01)
Ironwood earns $15M milestone from Astellas
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 8:31AM CST
IRWD: 13.80 (+0.10)
Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan
Business Wire - Thu Nov 20, 8:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that it has earned a $15 million development milestone payment from Astellas Pharma Inc., its partner for linaclotide in Japan. This milestone was triggered by Astellas's enrollment of the first patient in a randomized, double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with irritable bowel syndrome with constipation (IBS-C) in Japan. Astellas expects to complete the Phase III trial in 2016.
IRWD: 13.80 (+0.10)
Zytiga is Currently the Most Commonly Prescribed Second-Line Therapy for Metastatic Castrate-Resistant Prostate Cancer, According to Surveyed European Oncologists
PR Newswire - Tue Nov 18, 10:00AM CST
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5). The average reported patient share of Medivation/Astellas Pharma's Xtandi in the second-line mCRPC setting is comparable across the EU5 with the exceptions of Italy and Spain, where Xtandi is yet to complete pricing and reimbursement negotiations. Dendreon's Provenge and Bayer HealthCare's Xofigo received European approval in 2013, but have not yet completed pricing and reimbursement negotiations across all European countries; interviewed payers cite long delays in completing these negotiations, particularly in cost-constrained countries.
Global Overactive Bladder Therapeutics Market 2014-2018: Rise in Geriatric Population
M2 - Mon Nov 17, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/dd68fj/global_overactive) has announced the addition of the "Global Overactive Bladder Therapeutics Market 2014-2018" report to their offering. One major trend emerging in this market is the increase in awareness about overactive bladder syndrome. It results in an increase in the consumption of medications, thereby, contributing to the growth of the market. Overactive bladder is a urological condition associated with urination problems. The condition is characterized by bladder storage symptoms such as urgency, change in frequency of urination, nocturia, or urinary incontinence. It is also known as overactive bladder syndrome. Although it is not a life-threatening condition, it is often stigmatized and debilitating. Some of the important symptoms of overactive bladder are urinary urgency and incontinence. The pathophysiology of overactive bladder is not characterized completely. The symptoms of overactive bladder can last for a lifetime or it can relapse and remit. The problem can be resolved through treatment. Overactive bladder can affect a person irrespective of the gender. The reason is the abnormal contraction of the urinary detrusor muscle of the bladder. In addition, overactive bladder can be related to neurological diseases such as Parkinson's disease and multiple sclerosis. According to the report, the major driving factor of the market is the rise in the geriatric population suffering from various diseases, which are at risk of developing overactive bladder syndrome. This results in an increase in the consumption of drugs for overactive bladder, thereby, boosting growth. Further, the report states that the difficulty in diagnosis is a major challenge to the growth of the market. It results in fewer treatment-seeking patients, which, in turn, restrains the growth of the market. The diagnosis is done through clinical examination and a series of diagnostic tests to rule out the possibilities of bladder cancer, urinary tract infection, and benign prostatic hyperplasia. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of overactive bladder, which include: - Anti-muscarinic Agent - Beta-3-Adrenergic Receptor Agonist Key Vendors - Actavis - Allergan - Astellas Pharma - Pfizer For more information visit http://www.researchandmarkets.com/research/dd...overactive
AGN: 205.75 (-3.26)
FibroGen on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:46PM CST
IPO: 22.40 (-0.17), BIS: 50.05 (+1.20), BIB: 118.31 (-2.94), AZN: 69.56 (-0.18), IBB: 293.67 (-3.99), FGEN: 29.07 (+0.03)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.28 (+0.07), CRIS: 1.15 (-0.01), IMMU: 4.23 (+0.02), PCYC: 129.56 (+1.12), ONCY: 0.57 (unch), PFE: 30.67 (-0.19), LLY: 69.26 (-0.41), BMY: 57.69 (-0.86), GSK: 41.92 (+0.62), JNJ: 102.76 (-1.20), SNTA: 2.66 (+0.02), NVS: 91.65 (+0.01), XLRN: 37.63 (-0.37), ARRY: 4.59 (-0.04), CELGZ: 3.29 (-0.18), EXEL: 1.31 (-0.05)